Search results for NovoNordisk
NovoNordisk community
One keyword maps to one global community path.
People
Not Found
Tweets including NovoNordisk
GLP-1's benefits go beyond weight loss, Novonordisk CEO Mike Doustdar says.
From alcohol addiction, fertility, premenopausal symptoms, inflammation, and heart improvement, "People take these products, and they say my skin feels better," Doustdar tells @BrianSozzi.
Watch the full interview now.
Show more
📍Novo Nordisk CEO: China is becoming more central to the company's global strategy
#NovoNordisk# #China# #innovation# @zhang_heqing
@salahzhang
@consulat_de
@ChenPingMFA
@CGMeifangZhang
@salahzhang
@CNYouthDaily
Show more
Introducing new Wegovy savings on Ro—saving patients up to $1,200/year. With @novonordisk, we’re offering the lowest available cash prices and expanding access to effective, FDA-approved GLP-1s, with more ways to save on Ro’s Body membership coming soon.
Show more
Introducing the Wegovy pill—launched on Ro. By working directly with @novonordisk , we are giving patients nationwide access to this innovative new treatment Day 1 and with seamless delivery to their doors at the best cash price.
Show more
NOVO NORDISK: INVESTIGATIONAL CAGRISEMA 2.4MG/2.4MG SHOWED 25% AVERAGE WEIGHT LOSS IN WOMEN IN REDEFINE 1 POST HOC ANALYSIS
Novo Nordisk’s former CEO, Lars Fruergaard Jorgensen, is set to become the new chair of H. Lundbeck in his first major corporate role after last year’s surprise exit from the obesity-drug maker
Show more
NOVO NORDISK'S SEMAGLUTIDE 2 MG DOSE IS ASSOCIATED WITH A 6% LOWER RISK OF SERIOUS CARDIOVASCULAR EVENTS.
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui
Novo Nordisk will pay as much as $2.6 billion to license an experimental obesity pill from China’s Hengrui, as it seeks to rebuild investor confidence in its future beyond blockbusters Ozempic and Wegovy
Show more
